Acomplia Xagena










Year: 2010 2009 2008 2007 All

Acomplia

News

Page 1 of 2

Risk of psychiatric side effects is approximately doubled in patients taking Acomplia: The European Medicines Agency ( EMEA ) has completed a review of Acomplia ( Rimonabant ) at the request of the European Commission, following concerns over the medicine�s psychiatric safety. The Agency�s Committee for Medicinal Products for Human Use ( CHMP ) has concluded that the benefits of Aco...
Read Article

Rimonabant: safety issues: Rimonabant ( Acomplia / Zimulti ) is a cannabinoid receptor antagonist. It acts by blocking a specific type of receptor called cannabinoid type 1 ( CB1 ) receptors. These receptors are found in the nervous system and are part of the system that the body uses to control food intake. By blocking the r...
Read Article

Long-term pharmacotherapy for obesity and overweight: modest weight loss: Patients taking anti-obesity drugs will only see modest weight loss and many will remain significantly obese or overweight. The study, which looked at the long-term effectiveness of anti-obesity medications, found that three drugs recommended for long-term use � Orlistat ( Xenical ), Sibutramine ...
Read Article

EMEA recommends Acomplia must not be used in patients on antidepressants or with major depression: The EMEA ( European Medicines Agency ) has recommended contraindicating Acomplia ( Rimonabant ), in patients with ongoing major depression or who are being treated with antidepressants, because of the risk of psychiatric side effects. Doctors in the EU ( European Union ) have already been war...
Read Article

Obesity � Acomplia: loss of a few kilos, many questions: Acomplia ( Rimonabant ), a CB1 cannabinoid receptor antagonist, was approved by EMEA ( European Medicines Agency ) for the adjuvant treatment of obesity, in combination with a low-calorie diet and physical exercise. Rimonabant is used together with diet and exercise to treat adult patients: wh...
Read Article

Acomplia may be dangerous for women of reproductive age: Anandamide is a lipid signal molecule that was the first endogenous agonist for cannabinoid receptors to be discovered. Cannabinoid receptor type 1 ( CB1 ) is widely distributed in neurons and nonneuronal cells in brain and peripheral organs including sperm, eggs, and preimplantation embryos. A...
Read Article

Rimonabant, a new drug for weight loss: Rimonabant ( Acomplia ) is an oral selective cannabinoid CB1 receptor antagonist. It is licensed as an adjunct to diet and exercise for the treatment of obese patients( BMI >30Kg/m2 ), or overweight patients ( BMI >27Kg/m2 ) with associated risk factor(s), such as type 2 diabetes or dyslipidaemia. ...
Read Article

Rimonabant shows modest benefit in reducing weight, improving HDL, triglyceride levels: Use of the weight-loss medication Rimonabant ( Acomplia ) produced modest yet sustained weight loss after 2 years, and improved HDL cholesterol and triglyceride levels. Approximately two-thirds of U.S. adults are overweight or obese, which greatly increases the risk of developing diabetes mellitu...
Read Article

Integration of endocannabinoid and leptin signaling regulates the excitability of neurons on appetite-related circuits: Marijuana, or more specifically its active ingredient, tetrahydrocannabinol, has a well-documented tendency to stimulate hunger. And while researchers have traced this property to cannabinoid receptors in the brain, they have had little understanding of the neural circuitry underlying this effect....
Read Article

Type 2 diabetes, Rimonabant lowers blood glucose, reduces weight, waist size, and modifies lipids: Rimonabant ( Acomplia ) has demonstrated that it can lower blood glucose and reduce weight and waist circumference, as well as modify lipids associated with diabetic dyslipidemia, in patients with type 2 diabetes. Results of the RIO-Diabetes ( Rimonabant In Obesity ) study show impressive finding...
Read Article

Pages:1, 2 Next

Farmaci

Home

Farmacovigilanza

Progetto Farmaci